

CAREFUSION Corp  
Form 425  
October 10, 2014

Vince Forlenza  
CEO and Chairman  
BD  
FILED  
BY

BECTON,  
DICKINSON  
AND  
COMPANY  
PURSUANT  
TO  
RULE  
425  
UNDER  
THE  
SECURITIES  
ACT  
OF  
1933  
AND  
DEEMED  
FILED  
PURSUANT  
TO  
RULE  
14A-12  
OF  
THE  
SECURITIES  
EXCHANGE  
ACT  
OF  
1934  
SUBJECT  
COMPANY:  
CAREFUSION  
CORP  
COMMISSION  
FILE  
NO.  
001-34273

2

BD is a company with strong values and a track record of success

Announcement accelerates CareFusion's plans to build greater scale

New growth opportunities for products in emerging markets and

expands global reach by leveraging BD's international infrastructure

Offers a complete suite of medication management and patient safety solutions

The hard work of CareFusion's 17,000 employees got us here today

Key Highlights

3

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products  
Innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research  
30,000 employees in 50 countries who strive to fulfill the company's purpose of *Helping all people live healthy lives*  
HQ in Franklin Lakes, New Jersey

Who is BD?

A Leading Global Medical Technology Company

4  
1897  
Company founding  
1906  
First U.S. syringe and needle factory  
1924  
First insulin injection device  
1942  
First penicillin injection device

1949  
First evacuated blood collection tube  
1952  
First sterile disposable device  
1954  
First disposable syringes for Salk Polio campaign  
1962  
First mass produced syringes and needles  
1968  
First automated blood culture system  
1972  
First fluorescence activated cell sorter  
1988  
First safety-engineered syringe  
1991  
First auto-disable syringe  
1995  
BD Insyte  
Autoguard  
IV Catheter  
2002  
BD FACSAria  
Cell Sorter  
2006  
GeneOhm (HAIs) and TriPath (cancer Dx)  
2012  
KIESTRA Lab Automation  
BD Legacy of Health Impact

5

Advancing the quality, accessibility, safety and affordability of healthcare around the world

Long-standing relationships with non-governmental organizations

Social investment includes corporate grants, product donations, volunteer service initiatives and disaster relief programs

Donate time, technical expertise and resources

Associate engagement programs

International volunteer opportunities

Helping all people live healthy lives



6

118 years of successful legacy in the healthcare industry  
More than just a world-class quality medical technology  
company

Committed to addressing customer needs and foremost  
health priorities around the world

Conclusions

Tom Polen  
Segment President  
BD Medical

8

CareFusion Portfolio

BD Portfolio

In Medication Management, Our Combined Portfolios

Provide an End-to-End Solution from Pharmacy to Patient

End-to-End

medication

management

Solution

Reduction in  
Costs  
Labor  
Efficiency  
Drug Waste  
Inventory  
Smartworks  
Improvement  
in Quality

Med Errors

Infections  
TM

9  
Leading Global Infrastructure enables  
accelerated international expansion  
Updated September 2013  
BD in Western Europe

First  
location

-  
France  
-  
1952

Legal Entities in 21 countries

Ten plants

6,000 BD associates  
BD in Latin America

First  
location  
-  
Mexico

1952

Legal entities in eight countries

Five plants

5,200 BD associates  
BD in Asia Pacific  
BD In Japan

Established -  
1971

One plant

600 BD associates  
BD in EMA

First Location  
Dubai, UAE  
1994

Legal entities in ten countries

No manufacturing

250 BD associates  
Legal Entities  
Plant locations  
Corporate Office  
Emerging Markets  
BD In India

Established -  
1995

One plant

550 BD associates  
BD In China

Established -  
1994

Two plants

2,200 BD associates  
BD in Canada

Established

1951

One plant

550 BD associates  
BD in United States

Established

1897

29 plants

12,000 BD associates

First  
location

Australia, 1971

Legal entities in 16 countries

Five plants

4,600 BD associates

Bill Kozy  
COO  
BD



11  
Phases of integration  
Timing  
Phase I  
Phase II  
Listen, engage (and focus  
on business momentum)  
Jointly plan and  
countdown to close

Transition to NewCo  
2-4+ months

Key  
Activities  
First ~30 days  
Close to 2-3 years

Create the integration  
architecture and launch  
the integration teams  
(IMO, value capture and  
functional)

Develop talent selection,  
retention and business  
protection approach

Initiate baseline creation  
and target setting

Launch culture  
assessment and frequent  
communications

Develop Day 1/100 plans

Develop detailed synergy  
ideas and value creation  
plans

Countdown to close: lock  
targets, finalize plans and  
prepare for Day 1

Leverage culture insights  
in org design and Day 1  
plans

Execute Day 1/100 plans,  
onboard employees, track  
progress

Ensure culture integration  
and execute interventions  
Phase III

12

Integration project structure

Integration Management Office

Tom Jaeger

Chair

CareFusion

Vice Chair

Value Capture

Advisory Council

Bill Kozy

Chair

Chairman s Integration

Council

Vince Forlenza

Chair

Bill Kozy

Vice Chair

Function teams

Create NewCo infrastructure  
and capture cost synergies

BU/Geographic teams

Capture business value

Issue resolution teams

Resolve targeted issues

Team members drawn from both companies



### ***Forward-Looking Statements***

*This communication contains certain estimates and other forward-looking statements (as defined under Federal securities laws). Forward looking statements generally are accompanied by words such as will , expect , outlook or other similar words, phrases or expressions. These forward-looking statements include statements regarding the estimated or anticipated future results of BD, and of the combined company following BD s proposed acquisition of CareFusion, the anticipated benefits of the proposed combination, including estimated synergies, the expected timing of completion of the transaction and other statements that are not historical facts. These statements are based on the current expectations of BD and CareFusion management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding BD and CareFusion s respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the ability of the parties to successfully close the proposed acquisition, including the risk that the required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transaction; risks relating to the integration of CareFusion s operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; the outcome of any legal proceedings related to the proposed merger; access to available financing for the refinancing of BD s or CareFusion s debt on a timely basis and reasonable terms; the ability to market and sell CareFusion s products in new markets, including the ability to obtain necessary regulatory product registrations and clearances; the loss of key senior management or other associates; the anticipated demand for BD s and CareFusion s products, including the risk of future reductions in government healthcare funding, changes in reimbursement rates or changes in healthcare practices that could result in lower utilization rates or pricing pressures; the impact of competition in the medical device industry; the risks of fluctuations in interest or foreign currency exchange rates; product liability claims; difficulties inherent in product development, including the timing or outcome of product development efforts, the ability to obtain regulatory approvals and clearances and the timing and market success of product launches; risks relating*

to fluctuations in the cost and availability of raw materials and other sourced products and the ability to maintain favorable supplier arrangements and relationships; successful compliance with governmental regulations applicable to BD, CareFusion and the combined company; changes in regional, national or foreign economic conditions; uncertainties of litigation, as well as other factors discussed in BD's and CareFusion's respective filings with the Securities Exchange Commission. BD and CareFusion do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.

### **IMPORTANT INFORMATION FOR INVESTORS**

In connection with the proposed transaction, BD will file with the SEC a registration statement on Form S-4 that will constitute a prospectus of BD and include a proxy statement of CareFusion. BD and CareFusion also plan to file other relevant documents with the SEC regarding the proposed transaction. **INVESTORS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.** You may obtain a free copy of the proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by BD and CareFusion with the SEC at the SEC's website at [www.sec.gov](http://www.sec.gov). In addition, you will be able to obtain free copies of these documents by phone, e-mail or written request by contacting the investor relations department of BD or CareFusion at the following: Monique N. Dolecki, Investor Relations 201-847-5378 [Monique\\_Dolecki@bd.com](mailto:Monique_Dolecki@bd.com) or Jim Mazzola, Investor Relations 858-617-1203 [Jim.Mazzola@CareFusion.com](mailto:Jim.Mazzola@CareFusion.com)

### **PARTICIPANTS IN THE SOLICITATION**

BD and CareFusion and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about BD's directors and executive officers is available in BD's proxy statement dated December 19, 2013, for its 2014 Annual Meeting of Shareholders and subsequent SEC filings. Information about CareFusion's directors and executive officers is available in CareFusion's proxy statement dated September 25, 2014, for its 2014 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from BD or CareFusion as indicated above. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.